BioSTL

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

We are a European family office owned fund; we understand biosciences and medical technologies better than anyone else in the Private Equity and Venture Capital ecosystem. The capital of this fund has been generated by the family office's active bioscience investments across Europe, USA, and the APAC region since 1995. We understand the intricacies of commercializing bioscience discoveries. We also acknowledge that bioscience venture leadership requires deep courage - from founders and the investors that back them. What we look for We operate globally and only review investment opportunities submitted to us by our partner investment banks across the globe. If we believe in the transformative power of the discovery and the founder's ambition, this will suffice for us to determine the venture's potential. Our approach Upon receipt of a proposal from our investment bank partners, we will analyze the proposed deal, meet with the venture founders, and understand their vision. We will propose a deal size and structure. Execute a letter of intent and perform appropriate due diligence, negotiate, and execute a mutually acceptable binding contract. Release the required funding, close the transaction and work together to grow the business.

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

A force multiplier for scientists and innovators pushing the boundaries of what’s possible in biology and beyond. We are a team of biologists, engineers, and reformed finance people, but more importantly, we are... Thought partners Builders Optimists Allies We are here to serve our founders, their teams, and the visions they bring to life. Philosophy In the past decade, humanity has gained the ability to Store data on DNA Reprogram cells to kill cancer Train computers to read medical images Write in the code of life Engineer microbes to fix nitrogen for crops What makes all this possible? The Moore meets Mendel moment What it Means We believe we are in the early chapters of a new biological revolution. Data from novel Bio-Tools plus Artificial Intelligence and Machine Learning are generating major new insights in biology. These insights will create the next generation of biological products. And we upend the way we heal, clothe, consume, and protect. Our processThemes: Sydney Brenner said it best: “Progress in science depends on new techniques, new discoveries and new ideas, probably in that order”. As long-time investors in novel data-generation techniques, we are in a privileged position to identify major new themes and big ideas that emerge from this data. We prioritize areas with high potential for 'first-in-class' or 'best-in-class' applications. Research: We dive deep into our core themes, and focus on identifying major unmet needs. OMX has a mature network of founders, colleagues, and researchers who help us every step of the way to find standout companies and ideas. Select + Invest: When we see clear best-in-class solutions with a clear market fit, we invest early and get to work. We strive to earn the right every day by being reachable and generous with time, while at the same time having the technical and detail orientation to be more than a friendly ear. As part of your due diligence on us, we encourage you to reach out to the founders we have partnered with. Who: Anyone, anywhere! Many of the entrepreneurs who we support are first-time founders. For some, this is their third or fourth go round; and for others yet, this is their third or fourth time working with us.